Stock Events

Stock Events

Prostatype Genomics AB 

€0.007000
2
-€0.00-0% 08:55 Today

Statistics

Day High
0.007
Day Low
0.0048
52W High
0.133
52W Low
0.005
Volume
-
Avg. Volume
-
Mkt Cap
414,323
P/E Ratio
-
Dividend Yield
-
Dividend
-

Financials

-7,466.36%Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
54,252.56Revenue
-4.05MNet Income

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Myriad Genetics
MYGN
Mkt Cap607.38M
Myriad Genetics provides molecular diagnostic products that include prognostic medicine for prostate cancer, directly competing with Prostatype Genomics' offerings.
Illumina
ILMN
Mkt Cap35.63B
Illumina manufactures sequencing systems that are used in cancer genomics, impacting the broader market including prostate cancer diagnostics.
Fulgent Genetics
FLGT
Mkt Cap567.37M
Fulgent Genetics offers comprehensive genetic testing, including for cancer, which places them in direct competition with Prostatype Genomics in the genomic profiling market.
Pacific Biosciences of California
PACB
Mkt Cap809.71M
Pacific Biosciences offers sequencing technologies that are used in genomic research, including cancer, indirectly competing with Prostatype Genomics.
Qiagen NV
QGEN
Mkt Cap10.37B
Qiagen provides sample to insight solutions including for cancer, with technologies that compete in the genomic diagnostics market.
Quest Diagnostics
DGX
Mkt Cap27.79B
Quest Diagnostics offers diagnostic testing, including for cancers such as prostate cancer, competing with Prostatype Genomics in the diagnostics market.

About

Prostatype Genomics AB focuses on creating, marketing, and selling sophisticated prognostic gene tests. Their primary offering, the Prostatype Test System, combines genetic expression data with key clinical measurements such as PSA levels, Gleason Score, and Tumor Stage to determine a specific P-score. This advanced diagnostic tool is built upon a vast database of prostate cancer patients, providing crucial support for patients and medical practitioners when deciding on treatment strategies. Founded in 2007, the company is headquartered in Solna, Sweden.
Show More
CEO
Fredrik Rickman
Employees
7
Country
Sweden
ISIN
SE0023261532
WKN
000A40P4W

Listings

OTC Link
US
PGABF
ST
SE
PROGEN-BT-UN.ST
F
DE
PGO0.F
ST
SE
PROGEN.ST

0 Comments

Share your thoughts

FAQs

What is Prostatype Genomics AB stock price today?▼
The current price of PGO0.F is €0.01 EUR — it has decreased by -0% in the past 24 hours. Watch Prostatype Genomics AB stock price performance more closely on the chart.
What is Prostatype Genomics AB stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on Frankfurt Exchange exchange Prostatype Genomics AB stocks are traded under the ticker PGO0.F.
Is Prostatype Genomics AB stock price growing?▼
PGO0.F stock has risen by +2.94% compared to the previous week, the month change is a +12.9% rise, over the last year Prostatype Genomics AB has showed a -84.65% decrease.
What is Prostatype Genomics AB market cap?▼
Today Prostatype Genomics AB has the market capitalization of 414,323
What is Prostatype Genomics AB revenue for the last year?▼
Prostatype Genomics AB revenue for the last year amounts to 54,252.56 EUR.
What is Prostatype Genomics AB net income for the last year?▼
PGO0.F net income for the last year is -4.05M EUR.
How many employees does Prostatype Genomics AB have?▼
As of November 3, 2026, the company has 7 employees.
In which sector is Prostatype Genomics AB located?▼
Prostatype Genomics AB operates in the Health & Wellness sector.
When did Prostatype Genomics AB complete a stock split?▼
The last stock split for Prostatype Genomics AB was on October 31, 2024 with a ratio of 1:1000.
Where is Prostatype Genomics AB headquartered?▼
Prostatype Genomics AB is headquartered in Nacka Strand, Sweden.